SILO
MaterialsSilo Pharma, Inc. Common Stock
$0.42-0.03 (-6.65%)PRE
Live · XNAS · May 9, Close
AI Insight
What's Moving SILO Today?
No stock-specific AI insight has been generated for SILO yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume393K
Avg Volume (10D)—
Shares Outstanding16.3M
SILO News
20 articles- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·May 4, 2026
- Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In FocusBenzinga·Apr 7, 2026
- Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 1, 2025
- Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury ManagementYahoo Finance·Sep 29, 2025
- Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and SecurityYahoo Finance·Sep 23, 2025
- EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And SecurityYahoo Finance·Sep 23, 2025
- Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD DrugYahoo Finance·Sep 9, 2025
- EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven CancersYahoo Finance·Sep 2, 2025
- Silo Pharma Second Quarter 2025 Earnings: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024)Yahoo Finance·Aug 15, 2025
- Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15Yahoo Finance·Jul 16, 2025
- Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025Yahoo Finance·Jul 7, 2025
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trialYahoo Finance·Jun 27, 2025
- Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketYahoo Finance·Jun 25, 2025
- Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.Yahoo Finance·Jun 25, 2025
- Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsYahoo Finance·Jun 11, 2025
- Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15Yahoo Finance·May 21, 2025
- Silo Pharma Announces Closing of $2 Million Public OfferingYahoo Finance·May 16, 2025
- Silo Pharma Announces Pricing of $2 Million Public OfferingYahoo Finance·May 15, 2025
- Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15Yahoo Finance·May 14, 2025
- Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage LaboratoriesYahoo Finance·May 14, 2025
All 20 articles loaded
Price Data
Open$0.46
Previous Close$0.45
Day High$0.47
Day Low$0.45
52 Week High—
52 Week Low—
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume393K
Avg Volume (10D)—
Shares Outstanding16.3M
About Silo Pharma, Inc. Common Stock
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security Type—
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—